Correction: VEGF-A/VEGFR-1 signalling and chemotherapy-induced neuropathic pain: therapeutic potential of a novel anti-VEGFR-1 monoclonal antibody
verfasst von:
Laura Micheli, Carmen Parisio, Elena Lucarini, Alessia Vona, Alessandra Toti, Alessandra Pacini, Tommaso Mello, Serena Boccella, Flavia Ricciardi, Sabatino Maione, Grazia Graziani, Pedro Miguel Lacal, Paola Failli, Carla Ghelardini, Lorenzo Di Cesare Mannelli
Following publication of the original article [1], the authors identified an error in Fig. 6. The image representative of cell nuclei (DAPI staining) of the group “control” (panel “b”, first on the left) was unintentionally duplicated in panel “c” relative to the group “oxaliplatin” during the image assembly process by the authors.
The correction does not alter the scientific outcome since the result about the colocalization analysis of VEGF-A and GFAP in control and oxaliplatin-treated mice did not require the use of DAPI channel. The original article [1] has been corrected.
Incorrect Fig. 6
Fig. 6
VEGF-A is increased in spinal astrocytes of mice with oxaliplatin-induced neuropathy. (a) Representative images and quantitative analysis of mean VEGF-A fluorescence intensity in the dorsal horn of oxaliplatin-treated mice in comparison to control animals (vehicle, n = 13). (b-d) Colocalization analysis of VEGF-A and GFAP in control (b) and oxaliplatin-treated mice (c). Quantitative analysis of colocalization area (d) (vehicle, n = 13; oxaliplatin, n = 12). Scale bar: 100 μm; insert: 50 μm. Each value represents the mean ± SEM. *P < 0.05 vs vehicle group. The analysis of variance was performed by one-way ANOVA. A Bonferroni’s significant difference procedure was used as post-hoc comparison
×
Correct Fig. 6
Fig. 6
VEGF-A is increased in spinal astrocytes of mice with oxaliplatin-induced neuropathy. (a) Representative images and quantitative analysis of mean VEGF-A fluorescence intensity in the dorsal horn of oxaliplatin-treated mice in comparison to control animals (vehicle, n = 13). (b-d) Colocalization analysis of VEGF-A and GFAP in control (b) and oxaliplatin-treated mice (c). Quantitative analysis of colocalization area (d) (vehicle, n = 13; oxaliplatin, n = 12). Scale bar: 100 μm; insert: 50 μm. Each value represents the mean ± SEM. *P < 0.05 vs vehicle group. The analysis of variance was performed by one-way ANOVA. A Bonferroni’s significant difference procedure was used as post-hoc comparison
×
Anzeige
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Correction: VEGF-A/VEGFR-1 signalling and chemotherapy-induced neuropathic pain: therapeutic potential of a novel anti-VEGFR-1 monoclonal antibody
verfasst von
Laura Micheli Carmen Parisio Elena Lucarini Alessia Vona Alessandra Toti Alessandra Pacini Tommaso Mello Serena Boccella Flavia Ricciardi Sabatino Maione Grazia Graziani Pedro Miguel Lacal Paola Failli Carla Ghelardini Lorenzo Di Cesare Mannelli
Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.
Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.
Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.
Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.
Update Onkologie
Bestellen Sie unseren Fach-Newsletterund bleiben Sie gut informiert.
